Literature DB >> 16769987

Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.

Nikos Xenidis1, Maria Perraki, Maria Kafousi, Stella Apostolaki, Irene Bolonaki, Aliki Stathopoulou, Kostas Kalbakis, Nikos Androulakis, Charalambos Kouroussis, Thanos Pallis, Charalambos Christophylakis, Katerina Argyraki, Evi S Lianidou, Stathis Stathopoulos, Vassilis Georgoulias, Dimitris Mavroudis.   

Abstract

PURPOSE: To evaluate the predictive and prognostic value of peripheral blood cytokeratin-19 (CK-19) mRNA-positive cells in axillary lymph node-negative breast cancer patients. PATIENTS AND METHODS: Peripheral blood was obtained from 167 node-negative breast cancer patients before the initiation of any systemic adjuvant therapy, and was analyzed for the presence of CK-19 mRNA-positive cells using a real time polymerase chain reaction assay. The association with known prognostic factors and the effect of CK-19 mRNA-positive cells on patients' prognosis was investigated.
RESULTS: CK-19 mRNA-positive cells were detected in the blood of 36 (21.6%) of the 167 patients. There was no correlation between the detection of CK-19 mRNA-positive cells in the peripheral blood and the various known pathologic and clinical prognostic factors; only overexpression of HER2 receptor (score 2+/3+) on the primary tumor was associated with a higher incidence of CK-19 mRNA-positive cell detection (P = .033). Multivariate analysis revealed that detection of peripheral blood CK-19 mRNA-positive cells was associated with early clinical relapse (P < .00001) and disease-related death (P = .008).
CONCLUSION: Detection of peripheral-blood CK-19 mRNA-positive cells is an independent predictive and prognostic factor for reduced disease-free interval and overall survival, respectively, in node-negative breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769987     DOI: 10.1200/JCO.2005.04.5948

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  82 in total

Review 1.  Breast cancer assessment tools and optimizing adjuvant therapy.

Authors:  Catherine Oakman; Libero Santarpia; Angelo Di Leo
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

Review 2.  Gene expression profiling and DNA methylation analyses of CTCs.

Authors:  Evi S Lianidou
Journal:  Mol Oncol       Date:  2016-02-05       Impact factor: 6.603

Review 3.  Clinical Relevance of Disseminated Tumor Cells in the Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients.

Authors:  Volkmar Müller; Tanja Fehm; Wolfgang Janni; Gerhard Gebauer; Erich Solomayer; Klaus Pantel
Journal:  Breast Care (Basel)       Date:  2009-09-29       Impact factor: 2.860

4.  Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?

Authors:  Massimo Cristofanilli; John Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

5.  [Prognostic and predictive factors of invasive breast cancer: update 2009].

Authors:  T Decker; D Hungermann; W Böcker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

6.  Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years.

Authors:  J-Y Pierga; F-C Bidard; M G Denis; P de Cremoux
Journal:  Mol Oncol       Date:  2007-09-26       Impact factor: 6.603

Review 7.  Blood-based biomarkers in lung cancer: prognosis and treatment decisions.

Authors:  Meng Xu-Welliver; David P Carbone
Journal:  Transl Lung Cancer Res       Date:  2017-12

8.  Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Authors:  Todd M Morgan; Paul H Lange; Michael P Porter; Daniel W Lin; William J Ellis; Ian S Gallaher; Robert L Vessella
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 9.  Biophysical technologies for understanding circulating tumor cell biology and metastasis.

Authors:  Derrick W Su; Jorge Nieva
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 10.  Pancreatic cancer: Are "liquid biopsies" ready for prime-time?

Authors:  Alexandra R Lewis; Juan W Valle; Mairead G McNamara
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.